Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

One thing is for sure. You can't put a price on human life. But the estimates regarding the number of individuals coronavirus will kill are mind blowing and Ifenprodil has now been found by the worlds fastest supercomputer (see my previous post or AMG's nice links which highlight Ifenprodil in the list from the US Department of Energy) to potentially decrease the infectivity of the virus and also it's been shown in animal models to decrease mortality by 40%, big pharma will be willing to pay billions, because the global market will be multi-billions.

We are going to be running a trial in South Korea, way before anybody in North America can get FDA approval. We are way ahead of the game. We actually have a CRO who's going to run the trial (see below) and Korean physicians who will be running the trial:

AND They are going to run a trial in AUSTRALIA!!!!! Capturing the global market!

HOT OFF THE PRESS

VANCOUVER, British Columbia, March 20, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce today that it has chosen to appoint award winning Novotech as the contract research organization (“CRO”) for a planned physician initiated study of NP-120 (Ifenprodil) for COVID-19 infected patients in South Korea. Novotech is an internationally recognized full service CRO known for its experience across Australia, New Zealand, Asia and South Africa, representing emerging markets with a population base of over 3 billion people.

Novotech will be working to assist the investigators of the planned study, including supporting all aspects of the clinical trial. After the trial is approved, the Company will provide full details on the study protocol and timelines.

The Company also wishes to advise that it has retained Novotech to conduct a feasibility study in Australia for a phase 2 sponsor initiated Ifenprodil COVID-19 trial. Novotech has already identified 3 physicians who have indicated their interest to participate. The Company will update the market shortly.

“Novotech was a natural CRO choice for us to help to support this important investigator-led clinical trial,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “Since Ifenprodil is an already approved drug with a known safety history, we look forward to expedited steps that will make it available to patients as soon as possible under the study guidelines.”